ReviewDrug design, development and therapy2010
New approaches in the management of multiple sclerosis.
Review in Drug design, development and therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews.The Cochrane database of systematic reviews · 2019Pooled it
- Neuropsychological rehabilitation for multiple sclerosis.The Cochrane database of systematic reviews · 2014Pooled it
- Selected Cytokines and Matrix Metalloproteinases in Pathogenesis and Treatment of Multiple Sclerosis.International journal of molecular sciences · 2026Review
- Impact of Usual-Care Physiotherapy on Physical Activity and Self-Efficacy in People With Multiple Sclerosis: An Observational Longitudinal Study.International journal of MS care · 2025Article
- Raman liquid biopsy: a new approach to the multiple sclerosis diagnostics.Frontiers in neurology · 2025Article
- Cognitive telerehabilitation: an expert consensus paper on current evidence and future perspective.Frontiers in neurology · 2024Review
- Multiple sclerosis susceptibility may be associated with the coding rs20541 (R130Q) IL-13 gene polymorphism in the Polish population.Scientific reports · 2023Article
- Survival and Its Correlates in Multiple Sclerosis Patients under a Universal Health Insurance Program in Taiwan: An 18-Year Nationwide Cohort Study.Healthcare (Basel, Switzerland) · 2023Article
- Ultrasound-Guided Injections and Proprioceptive Neuromuscular Facilitation as Shoulder Rehabilitation for Multiple Sclerosis and Neuropathic Pain.Healthcare (Basel, Switzerland) · 2022Article
- Comment on "Alemtuzumab improves cognitive processing speed in active multiple sclerosis - a longitudinal observational study".Revista da Associacao Medica Brasileira (1992) · 2022Article
- Motor Cortical Activation Assessment in Progressive Multiple Sclerosis Patients Enrolled in Gait Rehabilitation: A Secondary Analysis of the RAGTIME Trial Assisted by Functional Near-Infrared Spectroscopy.Diagnostics (Basel, Switzerland) · 2021Article
- Moderating effects of crocin on some stress oxidative markers in rat brain following demyelination with ethidium bromide.Heliyon · 2019Article
- The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.Journal of neurology · 2017Review
- Disulfiram and Diphenhydramine Hydrochloride Upregulate miR-30a to Suppress IL-17-Associated Autoimmune Inflammation.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016Article
- Investigation of IL-21 gene polymorphisms (rs2221903, rs2055979) in cases with multiple sclerosis of Azerbaijan, Northwest Iran.American journal of clinical and experimental immunology · 2015Article
- Uses of complementary and alternative medicine in multiple sclerosis.Journal of traditional and complementary medicine · 2014Review
- Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- The promoter SNP, but not the alternative splicing SNP, is linked to multiple sclerosis among Jordanian patients.Journal of molecular neuroscience : MN · 2014Article
- Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances.The Lancet. Neurology · 2014Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a central nervous system chronic inflammatory disease that is characterized by an extensive and complex immune response. Scientific advances have occurred in immunology, pathophysiology, and diagnostic and clinical assessment tools, and recent discovery of unique therapeutic targets has spurred numerous Phase II and Phase III clinical trials. Reductions in MS relapse rates and improvements in T₂ or gadolinium-enhancing lesion burdens have been reported from Phase III trials that include fingolimod, alemtuzumab, cladribine, and rituximab. Promising Phase II trial data exist for teriflunomide, daclizumab, laquinimod, and fumarate. The optimism created by these favorable findings must be tempered with evaluation of the adverse effect profile produced by these new agents. Given the discovery of progressive multifocal leukoencephalopathy with the use of natalizumab, ongoing vigilance for rare and life-threatening reactions due to new agents should be paramount. Patients with MS often experience difficulty with ambulation, spasticity, and cognition. Recent clinical trial data from two Phase III dalfampridine-SR trials indicate certain patients receive benefits in ambulation. This article provides an overview of data from clinical trials of newer agents of potential benefit in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.